These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 2751745

  • 21. Serum lipoproteins in patients with myocardial infarction.
    Kauppinen-Mäkelin R, Nikkilä EA.
    Atherosclerosis; 1988 Nov; 74(1-2):65-74. PubMed ID: 3214482
    [Abstract] [Full Text] [Related]

  • 22. [Study of lipids (cholesterol, triglycerides and phospholipids), plasma lipoproteins (HDL-cholesterol) and apoproteins (apo A and apo B in patients with acute myocardial infarction].
    Paniagua J, Martínez Muñoz A, Tuset N, Gras J.
    Med Clin (Barc); 1989 Jun 24; 93(4):134-8. PubMed ID: 2796436
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
    Oida K, Nakai T, Tamai T, Kutsumi Y, Kobayashi T, Hayashi T, Yamada S, Takeda R.
    Artery; 1982 Jun 24; 10(4):266-85. PubMed ID: 7181672
    [Abstract] [Full Text] [Related]

  • 25. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
    Granata A, Sobbrio GA, D'Arrigo F, Barillari M, Curasì MP, Egitto M, Trimarchi F, Granese D, Pullè C.
    Acta Eur Fertil; 1990 Jun 24; 21(3):143-6. PubMed ID: 2149913
    [Abstract] [Full Text] [Related]

  • 26. Metabolic effects of a biphasic oral contraceptive preparation containing ethinyloestradiol and desogestrel on serum lipoproteins and apolipoproteins.
    Voorhoof L, Rosseneu M, Caster H, De Keersgieter W.
    J Endocrinol; 1986 Oct 24; 111(1):191-6. PubMed ID: 2946795
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Lipids, lipoproteins, apolipoproteins, and other risk factors in Chinese men and women with and without myocardial infarction.
    Schwartzkopff W, Schleicher J, Pottins I, Yu SB, Han CZ, Du DY.
    Atherosclerosis; 1990 Jun 24; 82(3):253-9. PubMed ID: 2375789
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH.
    Am J Cardiol; 1995 Jul 13; 76(2):129A-135A. PubMed ID: 7604788
    [Abstract] [Full Text] [Related]

  • 34. Postprandial remnant-like lipoproteins in hypertriglyceridemia.
    Ooi TC, Cousins M, Ooi DS, Steiner G, Uffelman KD, Nakajima K, Simo IE.
    J Clin Endocrinol Metab; 2001 Jul 13; 86(7):3134-42. PubMed ID: 11443178
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Lipid and apoprotein modifications in body builders during and after self-administration of anabolic steroids.
    Baldo-Enzi G, Giada F, Zuliani G, Baroni L, Vitale E, Enzi G, Magnanini P, Fellin R.
    Metabolism; 1990 Feb 13; 39(2):203-8. PubMed ID: 2105436
    [Abstract] [Full Text] [Related]

  • 38. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).
    Hartgens F, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel BH.
    Br J Sports Med; 2004 Jun 13; 38(3):253-9. PubMed ID: 15155420
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
    Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV.
    J Clin Invest; 1986 Nov 13; 78(5):1287-95. PubMed ID: 3095375
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.